Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-DR9 and DR14 are associated with the allopurinol-induced hypersensitivity in hematologic malignancy.

The Tohoku journal of experimental medicine - 1 Jun 2014

Jung Jae-Woo, Kim Ju-Young, Yoon Sung-Soo, Cho Sang-Heon, Park Seon-Yang, Kang Hye-Ryun

Abstract excerpt

Allopurinol, a widely used urate-lowering agent, is a leading cause of severe cutaneous adverse reactions (SCARs), especially in patients with HLA-B*58:01. Despite its routine use for the prevention of tumor lysis-related hyperuricemia prior to chemotherapy, the risk of allopurinol-induced hypersensitivity has not been investigated in patients with hematologic malignancies. This retrospective cohort study was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Allopurinol

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Asian People

Share to Gene Frequency

Share to Hematologic Neoplasms

Share to HLA-DR Serological Subtypes

Share to Hypersensitivity

Share to Republic of Korea

Source

Identifiers

PMID: 24858023
DOI: 10.1620/tjem.233.95

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-DR9 and DR14 are associated with the allopurinol-induced hypersensitivity in hematologic malignancy.PMID 24858023Read ↗

Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions.Semantic proximity Read ↗

Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.Semantic proximity Read ↗

HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.Semantic proximity Read ↗

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Semantic proximity Read ↗

Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.Semantic proximity Read ↗

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Semantic proximity Read ↗

An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing.Semantic proximity Read ↗

HLA-B*58:01 is an Incomplete Predictor of Allopurinol-Induced Severe Cutaneous Adverse ReactionsSemantic proximity Read ↗

Pharmacogenetics of hypersensitivity drug reactions.Semantic proximity Read ↗

Pharmacogenetics of allopurinol--making an old drug safer.Semantic proximity Read ↗

Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.